Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03427567
NCT03427567CompletedNot Applicable

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer

Tongji Hospital10 sites in 1 country3,902 target enrollmentStarted: December 1, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
3,902
Locations
10
Primary Endpoint
Overall survival
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer

Detailed Description

This is a multi-centre real-world non-interventional observational study. The study data on patient demographic/tumor biological characteristics and clinical treatments were retrospectively collected to evaluate effectiveness of sublobar dissection in the Chinese patients with non-small cell lung cancer who received sublobar dissection.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients >= 18 years old;
  • •Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections);
  • •Patients who received selective or systematic lymphadenectomy;
  • •Pathologically diagnosed patients with non-small cell lung cancer;
  • •Pathological staging: I, II

Exclusion Criteria

  • •Patients who received cancer treatments before surgeries (adjuvant therapies including chemotherapies, radiotherapies, target therapies);
  • •Patients who received late-phase or intolerant palliative lobectomy or compromise sublobar dissection;

Outcomes

Primary Outcomes

Overall survival

Time Frame: 2014 - 2017

Overall survival

Secondary Outcomes

  • Overall survivals in subgroups(2014 - 2017)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

XiangNing Fu

Professor

Tongji Hospital

Study Sites (10)

Loading locations...

Similar Trials

Completed
Not Applicable
A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung CancerNon-small Cell Lung Cancer
NCT03429192Tianjin Chest Hospital2,653
Completed
Not Applicable
Non-Invasive Ventilation Preoperative Lung Resection SurgerySurgery for Primary Lung Cancer
NCT01685580University Hospital, Brest300
Recruiting
Not Applicable
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNon-small Cell Lung Cancer
NCT05363319Regeneron Pharmaceuticals500
Completed
Not Applicable
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666
NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
Completed
Phase 2
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Cancer
NCT00051974Millennium Pharmaceuticals, Inc.155
A Study to Evaluate Effectiveness of... | Clinical Trial